Women with uterine fibroids stand to gain routine access to a non-surgical treatment on the National Health Service for the first time, after cost regulators endorsed Gedeon Richter's once-daily pill Esmya as an option.
Cell Medica has signed a research deal with University College London for access to its novel T cell receptor technology, in a bid to generate leading-edge modified TCR products for the treatment of cancer.
The National Institute for Health and Care Excellence has published two sets of guidelines increasing the treatment options for NHS patients with chronic myeloid leukaemia and non-small cell lung cancer.
AbbVie venetoclax has been accepted onto the UK's Early Access to Medicines Scheme (EAMS), having picked up a positive scientific opinion from the Medicines and Healthcare products Regulatory Agency for the treatment of chronic lymphocytic leukaemia.
Cost regulators are now backing NHS use of Bayer's Eylea for all patients with visual impairment due to branch retinal vein occlusion (BRVO), having initially recommended its use only in the second-line setting.